Awakn intends to run a Phase III trial for ‘Ketamine-Assisted Psychotherapy for Alcohol Use Disorder’ London, United Kingdom–(Newsfile Corp. – March 2, 2021) – Awakn Life Sciences Inc., a clinical-biotech company researching, developing, and delivering psychedelic medicine to treat addiction and other mental health conditions, today announced an exclusive license to use and deliver the ‘Ketamine…


Previous articleCan Psilocybin and LSD Relieve Existential Suffering?
Next articleMINDCURE Announces Manufacturing of Synthetic Ibogaine to be Used in Company’s Clinical Research